Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-03 (roastbrief.com.mx)
Biogen launches a campaign created by VML The Cocktail to raise awareness about Friedreich's ataxia, a rare neurodegenerative disease -
Give visibility and generate awareness of the reality that patients with Friedreich (AF) ataxia live is the objective of Friedreich and I. A
Read more
2024-09-03 (biospace.com)
Dyne Touts ‘Unprecedented’ Dystrophin Expression in Phase I/II DMD Trial for Exon-Skipping Therapy
The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment.
Read more
2024-06-17 (wsj.com)
Two Is Better Than One in the Alzheimer's Market
Approval of Eli Lilly's Alzheimer's drug donanemab could help build momentum for Biogen's struggling drug Leqembi.
Read more
2023-01-18 (fiercepharma.com)
AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out
Once again, biopharma companies offered hefty discounts to secure national reimbursement in China in the hopes that wider coverage in a fast-growing pharmaceutical market can offset price concessio| Innovative drugs from AbbVie, Novartis and Roche are among 111 therapies that won China 's national
Read more
2019-12-06 (skipr.nl)
BIOGEN is going to Alzheimermedicijn -
The American pharmaceutical group Biogen and his Japanese partner Eisai are sailing behind the development of their experimental means for the treatment of Alzheimer's disease. A research panel at a pharmaceutical conference in the United States mentions the new test results for the drug Aducanumab a "milestone".
Read more